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Abstract
Background: Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of
sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant
metastases.
Methods: Twenty five patients with oligometastases, defined as 1–5 sites of active disease on whole body imaging, were
enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney
and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1–28) and
IGRT 50 Gy (days 8–12 and 15–19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months
(range, 0.7 to 37.4 months).
Results: The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%,
56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive
with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%)
was dead from treatment-related toxicities. The incidence of acute grade $ 3 toxicities was 28%, most commonly
myelosuppression, bleeding and abnormal liver function tests.
Conclusions: Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases.
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Introduction
The standard non-surgical approach to distant metastases from
solid tumors is systemic therapy alone with radiation therapy
reserved for palliation of local symptoms [1]. In the setting of
oligometastases, defined as metastatic deposits that are limited in
number and location, incorporating local therapy is a conceptually
attractive approach [2]. Five recently published clinical trials
demonstrated high rates of local control for lung, liver, bone,
adrenal, soft tissue and lymph node metastases treated with
intensive radiation dose-fractionation schedules using image-
guided stereotactic radiotherapy [3–7]. The rationale for admin-
istering curative-intent radiation for oligometastases is that a
proportion of these patients will have durable remissions with an
acceptable toxicity profile [1]. In these studies, approximately 20%
of patients remained free of recurrence several years after
treatment when all sites of disease can be targeted by radiation
[7,8]. However, most patients develop additional distant metas-
tases within months of treatment [4–7]. These data highlight the
need for effective systemic agents for the majority of patients. In
turn, clinical models suggest that the relative importance of
effective local therapy increases as systemic therapy becomes more
effective [9].
Testing the hypothesis that distant metastases can be delayed or
prevented by systemic therapy requires an approach similar to
adjuvant treatment of primary cancers. In the studies recently
reported by Rusthoven et al. and Lee et al., chemotherapy was
discontinued for at least 4 weeks before, during and after
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e36979stereotactic body radiation to sites of metastatic involvement
[3,5,6]. In contrast, concurrent systemic therapy offers radiosen-
sitization and simultaneously addresses the competing risks of local
and distant progression [10]. Choosing a rational systemic agent
for the heterogeneous population of oligometastasis is a challenge.
With the hypothesis that targeting angiogenesis and tumor-
mediated immune suppression represents an important target in
most types of cancer, we identified sunitinib, a multitargeted
tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3,
PDGFR, c-kit, FLT3 and ret, as a potential enhancer of response
to radiotherapy [11,12]. In addition to effects on angiogenesis, our
group demonstrated robust effects of sunitinib on immunosup-
pressive myeloid-derived suppressor cells (MDSC) [13]. MDSC
and T regulatory cells (Treg) are important mediators in immune
suppression. In our preclinical model, treatment with sunitinib
decreased the number of MDSC and Treg in tumor-bearing mice
[13]. We have previously reported phase I results from a clinical
trial of concurrent sunitinib and hypofractionated image-guided
radiation therapy for patients of oligometastases with a 1-year
progression-free survival of 44% [14]. We now report results of a
phase II trial investigating concurrent sunitinib and image-guided
radiation therapy for patients with oligometastases.
Methods
Ethics Statement
The study (NCT00463060) was approved by the Mount Sinai
School of Medicine institutional review board, and was conducted
in accordance with federal and institutional guidelines. All patients
signed written informed consent. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Patient Eligibility
Patient eligibility was described previously [14]. Briefly,
eligible patients had pathologically confirmed solid tumor
malignancy with 1 to 5 sites of active metastatic disease on
whole body imaging (PET or CT chest, abdomen, pelvis and
bone scan) measuring #6 cm. Other key eligibility criteria
included age $18 years, Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2, and adequate hematologic,
hepatic and renal function. Eligibility required prior chemo-
therapy or radiation to be discontinued for at least 2 weeks
before study entry. Patients were excluded if they had
uncontrolled brain metastases, malignant pleural or pericardial
effusion, life expectancy ,3 months, prior radiation to targeted
area(s) or uncontrolled intercurrent illness. Due to fatal bleeding
occurring in a patient receiving anticoagulant therapy, the trial
was amended to exclude patients with a history of non-inducible
bleeding or who required continuation of anticoagulation during
study treatment. Between February 2008 and September 2010,
26 patients were enrolled on the study. One patient withdrew
prior to starting treatment due to declining performance status,
and was excluded from analysis.
Drug Administration
Based on phase I data, the phase II regimen of sunitinib was
37.5 mg daily on days 1–28. Sunitinib was administered orally
once daily in 6-week cycles consisting of 4 weeks of treatment
followed by 2 weeks without treatment. Sunitinib was provided
by Pfizer. After completion of concurrent sunitinib and
radiotherapy, the treating medical oncologist had the option
of continuing on maintenance sunitinib for additional cycles if
there was no unacceptable toxicity or progression. If patients
did not receive maintenance sunitinib, patients generally
received alternative chemotherapy, biological therapy or hor-
monal therapy, unless limited by age or performance status.
Radiation Guidelines
Radiation was administered concurrently with the first cycle
of sunitinib from days 8–12 and 15–19. Each patient’s
treatment was individualized with respect to immobilization
and radiation planning technique to optimally cover the target
volume and adequately account for organ motion while
adhering to strict normal tissue dose and volume limits, as
described previously [14]. All patients underwent CT simulation
with custom immobilization using an Alpha Cradle, Vac Lock
bag or Aquaplast mask. For lung and abdominal tumors,
maximum inspiratory, expiratory and free-breathing CT scans
were fused to document the maximum amplitude of tumor
motion for estimation of an ITV. Relaxed end expiratory breath
holding, forced shallow breathing and/or external optical
tracking often supplemented with an abdominal belt was
utilized for tumors with documented respiratory motion. The
gross tumor volume (GTV) was defined as gross tumor on CT,
MRI and/or PET. GTV to planning target volume (PTV)
expansion ranged from 0.5–1.5 cm, depending on extent of
organ motion with consideration for the proximity to critical
structures. The recommended phase II dose is 50 Gy in ten
fractions over two weeks. Dose was prescribed to the PTV with
.90% of the target receiving the prescription dose and a 3D
maximum of ,110%. When necessary due to the immediate
proximity to critical serial structures (e.g., spinal cord, small
bowel, esophagus), normal tissue protection was prioritized
above target coverage. Planning constraints on organs at risk
were described earlier [14]. Treatment planning consisted of
conformal arcs, intensity modulated radiation or 3-dimensional
forward planning. Daily image guidance was mandatory using
implanted fiducial markers or bone fusion.
Follow-up and Study End Points
The primary end point for the phase II trial was PFS
measured at 2 years post-therapy. Follow-up visits were planned
1 month after completing radiation therapy (RT) and every 3
months subsequently for 2 years. Patients underwent diagnostic
imaging studies before all follow-up visits after the initial 1-
month visit. Toxicity was assessed in patients at regular intervals
by using the Common Terminology Criteria for Adverse Events
(version 3.0). Tumor response was assessed using Response
Evaluation and Criteria in Solid Tumors (RECIST), which was
modified to incorporate PET/CT information [15]. Local in-
field recurrence was defined as progression or recurrence within
the high-dose region (.80% isodose volume). Actuarial survival
and disease control rates were evaluated by the Kaplan-Meier
method. Cause of death was ascertained and attributed to local
progression, distant progression, comorbid illness or treatment-
related toxicity.
Correlative Immune Studies
Peripheral blood mononuclear cells were isolated and analyzed
after Ficoll-Hypaque fractionation from 5 patients treated with
sunitinib and concurrent IGRT with advanced cancer. Specimens
were collected on days 0 (prior to starting sunitinib) and 7 (after 7
days of sunitinib but before starting IGRT). Cells were stained
using fluorochrome-conjugated antibodies to identify the following
immunophenotypes: CD4+, CD8+ (T cells); HLA-DR+/CD19+/
CD86+ (B cells); CD303+/CD123+ (plasmacytoid dendritic cells;
pDC); Lin-/HLA-DR-/CD11b+/CD33+ (MDSC); CD14+
Concurrent Sunitinib and IGRT for Oligometastases
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The percent increase or decrease in these cell populations was
determined and expression levels of surface markers were
quantified by mean fluorescence intensity. The data from
individual patients was compared before and after 7 days of
sunitinib treatment.
Statistical Considerations
The primary end point was PFS, measured as time from the
initiation of non-surgical treatment until last follow-up or disease
progression using intent to treat principles. Failures were scored as
local, regional or distant. Overall survival is defined as the
proportion of patients who are alive since the start of treatment.
Local control is defined as the absence of local failure, with the
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0036979.g001
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18F-FDG tumor SUV of .25% within
tumor region defined on baseline scan, or (2) a visible increase in
the extent of
18F-FDG tumor uptake (20% in longest dimension).
Distant control is defined by the absence of new
18F-FDG uptake
in metastatic lesions not identified on baseline (pre-treatment)
imaging. Progression-free survival is defined as survival in the
absence of local or distant progression, with the criteria of (1) an
increase in
18F-FDG tumor SUV of .25% within tumor region
defined on baseline scan, (2) a visible increase in the extent of
18F-
FDG tumor uptake (20% in longest dimension), or (3) the
appearance of new
18F-FDG uptake in metastatic lesions not
previously identified. For analysis of overall survival and progres-
sion-free survival, deaths were considered events.
Statistical analyses and Kaplan-Meier survival curves were
calculated using PASW Statistics 18 (IBM SPSS Statistics,
Armonk, NY). Tables were generated by Microsoft Excel 2010
Table 1. Baseline Patient Characteristics.
Variable Number (%)
Median age 63 (range 54–83)
50–69 16 (64%)
$70 9 (36%)
Sex
Male 18 (72%)
Female 7 (28%)
ECOG performance status
0 4 (16%)
1 13 (52%)
2 8 (32%)
Previous chemotherapy
No 12 (48%)
Yes 13 (52%)
Prior RT
No 15 (60%)
Yes 10 (40%)
Number of metastases
1 13 (52%)
2 5 (20%)
$3 7 (28%)
Largest tumor size
#3c m 15 (60%)
.3c m 10 (40%)
Number of involved organs
1 20 (80%)
$ 2 5 (20%)
Treatment site 49 total tumors
Bone 21 (43%)
Lung 14 (29%)
Lymph node 8 (16%)
Visceral (adrenal, thyroid, inferior vena cava, chest wall) 6 (12%)
Tumor type
Head and neck squamous cell carcinoma 4 (16%)
Hepatocellular carcinoma 4 (16%)
Non-small cell lung carcinoma 4 (16%)
Renal cell carcinoma 4 (16%)
Prostate adenocarcinoma 2 (8%)
Colorectal adenocarcinoma 2 (8%)
Pancreatic adenocarcinoma 1 (4%)
Melanoma 1 (4%)
Other (sarcoma, breast, skin squamous cell, parotid, thyroid, small cell lung) 3 (12%)
doi:10.1371/journal.pone.0036979.t001
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report the quantitative pre- and post-treatment immune responses
(mean6SD, 10
5 cells per mL). The paired Student’s t test was used
to compare the groups and p#0.05 was considered to be
statistically significant.
Results
Patients
Between February 2008 and September 2010, 25 patients with
49 discrete metastases were treated on protocol (Figure 1). The
median follow up for surviving patients was 17.5 months (range,
0.7 to 37.4 months). Baseline characteristics for all treated
patients are listed in Table 1. The most common tumor types
treated were head and neck, liver, lung, kidney, and prostate
cancers. The most common sites of metastases treated were
bone, lung and distant lymph nodes. Twenty-two patients (88%)
received treatment as per protocol. One patient discontinued
radiation and sunitinib after a dose of 25 Gy secondary to acute
toxicity. Two patients received a reduced dose of 40 Gy due to
the judgment of the treating radiation oncologist, and these were
classified as protocol violations. Maintenance sunitinib was used
in 32% of patients.
Patterns of Failure and Survival
At last follow-up, 11 (44%) patients were alive without evidence
of disease, 7 (28%) were alive with distant metastases, 3 (12%) were
dead from distant metastases, 3 (12%) were dead from comorbid
illness, and 1 (4%) was dead from treatment-related toxicities. The
18-month estimates for local control and distant control were 75%
and 52%, respectively. The 18-month estimates for PFS and OS
were 56% and 71%, respectively (Figure 2). The median time to
PFS was 9.5 months and the median survival has not been
reached. A representative patient treated with concurrent sunitinib
and IGRT is shown in Figure 3.
Toxicity
The most common grade $3 acute toxicities were neutropenia,
thrombocytopenia, bleeding and liver function test abnormalities.
Taken together, 28% of patients experienced at least one grade
$3 toxicity. Toxicities are described in Table 2. All grade $3
events, include one case of grade 5 gastrointestinal hemorrhage,
were considered likely related to sunitinib rather than radiother-
apy. The 4 deaths attributed to comorbid illness all occurred in
patients who discontinued sunitinib for at least 30 days prior to
death and were considered unlikely to be related to protocol
therapy. These deaths included 2 patients with cardiopulmonary
arrest and 1 elderly patient who died peacefully at home. One
patient with small cell lung cancer underwent autopsy that
demonstrated bronchobiliary fistula outside of the radiation field
in a patient who underwent 6 prior lung and liver surgeries.
Notably, there was no pathological evidence of residual small cell
lung cancer.
Immune Responses
Compared to pretreatment levels, cancer patients have signif-
icantly increased average number of CD4+ T cells after 7 days
of sunitinib treatment (3.1760.92610
5 to 3.6360.84610
5; paired
t-test, p=0.04). There was a significant decrease in the average
of number of Lin-CD33+ MDSC cells (2.2060.95610
5 to
Figure 2. Kaplan-Meier survival curves. a) Overall survival. b) Local
control. c) Distant control. d) Progression-free survival.
doi:10.1371/journal.pone.0036979.g002
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5; p=0.02), plasmacytoid dendritic cells
(0.0360.01610
5 to 0.0260.01610
5; p=0.01) and T-regulatory
cells (0.2860.05610
5 to 0.2660.04610
5; p=0.06). Although an
increase in CD8+ T cells was detected in some patients, this failed
to reach statistical significance.
Discussion
In this manuscript, we report results of a prospective phase II
trial investigating the efficacy of concurrent sunitinib and
hypofractionated IGRT for the treatment of patients with one to
five distant metastases from solid tumors. At a median follow-up of
17.5 months, the 18 month PFS was 56%, with 6 patients who
remain alive and free of disease progression at 18 to 37+ month
follow-up. Various pathologies were represented among long-term
survivors, including renal cell carcinoma, hepatocellular carcino-
ma, hormone-refractory prostate cancer and non-small cell lung
cancer. In addition to previously published phase I data, these data
support the notion that durable complete clinical and radiographic
remissions can be achieved in a subset of patients with
oligometastases treated with both local and systemic therapy.
In contrast to published studies investigating radiation alone for
oligometastases, concurrent sunitinib and radiation is associated
with a higher rate of acute grade $3 toxicity [3–7]. Although
toxicity from sunitinib is generally manageable, serious toxicities,
including grade 5 hemorrhage, were noted. Radiation of large
volumes of bone marrow and liver can exacerbate hematological
toxicities associated with sunitinib. Therefore, although 50 mg is
tolerable when sunitinib is administered as monotherapy, when
concurrent sunitinib is given with radiation, a reduced daily dose
of 37.5 mg is recommended [14]. Further, sunitinib should be
used with extreme caution in patients with a history of non-
inducible bleeding and patients requiring anticoagulation or
antiplatelet medication during treatment [16]. Taken together,
Figure 3. Representative patient treated with concurrent
sunitinib and IGRT. a) Pretreatment PET/CT demonstrates a biopsy
proven solitary metastasis in the right 7
th rib in a patient with non-small
cell lung cancer. b) The rib lesion was treated with Novalis using
dynamic arcs using the ITV method with an abdominal belt used to
dampen respiratory motion. Daily kV imaging was accomplished using
bone fusion. There was excellent coverage of the PTV with selective
sparing of the normal lung, liver and skin. c) Complete response on PET/
CT 23 months after Sutent +RT.
doi:10.1371/journal.pone.0036979.g003
Table 2. Adverse Events.
Adverse Event All grades Grade 3 Grade 4 Grade 5
Anemia 18 2 0 0
Neutropenia 14 2 0 0
Fatigue 18 0 0 0
LFT abnormalities 15 1 0 0
Thrombocytopenia 15 4 0 0
Mucositis/stomatitis 8 0 0 0
Nausea/vomiting 7 0 0 0
Skin changes 4 0 0 0
Diarrhea 5 0 0 0
Hypertension 3 0 0 0
Bleeding 4 1 0 1*
Metabolic abnormalities 2 1 (PO4)0 0
Increased creatinine 5 0 0 0
*One case occurred after sunitinib treatment and was likely related to
reirradiation performed prior to protocol therapy.
doi:10.1371/journal.pone.0036979.t002
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OS are superior to either sunitinib or radiation alone.
Two recently published clinical trials reported promising rates
of PFS in patients with oligometastases treated with radiation
alone (see Table 3). The University of Rochester published the
largest phase II experience of hypofractionated IGRT for
oligometastases mainly treated with 50 Gy in 10 fractions [4].
Milano et al. reported a 2-year PFS of 26%; patients with breast
cancers (32% of total patients) had the highest PFS while patients
with pancreatic and hepatobiliary tumors had the lowest PFS [4].
A phase I trial of stereotactic body radiotherapy (SBRT) to a dose
of 24–60 Gy in 3 fractions at the University of Chicago
demonstrated a crude 21% rate of freedom from progression at
a median follow-up of 15 months [7]. Although not strictly limited
to oligometastases, three recently reported phase I/II trials
investigating SBRT (36–60 Gy in 3–6 fractions) for lung and liver
metastases demonstrated promising local control rates of 71–96%,
although 64–83% developed distant progression at 4–6 month
median follow-up [3,5,6]. Due to small sample sizes and
heterogeneous populations enrolled in these studies, a potential
clinical benefit of adding concurrent systemic therapy to radio-
therapy for patients with oligometastases cannot be excluded.
Although not directly comparable to studies investigating
systemic therapy alone for stage IV cancer, a complete under-
standing of natural history of metastases treated without local
therapy may inform future research. Median PFS with palliative
systemic therapy alone for stage IV breast, colorectal, non-small
cell lung and hormone-refractory prostate cancers ranges from 2–
12 months [17–26]. In the two trials with the highest PFS that
investigated combinations of biological agents in combination with
conventional chemotherapy as first line treatment for breast and
colorectal cancer, the 2 year PFS was in the 10–15% range
[19,21]. Median PFS for metastatic renal cell carcinoma with
sunitinib was 11 months with a 2-year PFS of less than 20% [27].
A recent analysis of patients with metastatic lung cancer treated
with first-line chemotherapy alone demonstrates that the vast
majority of patients treated with drug therapy alone ultimately
progress, often at sites of initial bulk [28]. These data suggest that
sustained long-term remissions are only possible if both local and
systemic disease are adequately treated. However, a randomized
trial is necessary to definitively demonstrate a benefit for
concurrent sunitinib and radiation, compared to either treatment
alone.
Although combining radiation with angiogenesis inhibitors has
been extensively studied in animal models, a significant benefit for
local control or survival has not yet been shown in humans [29].
This study demonstrates the feasibility of combining sunitinib, a
multitargeted tyrosine kinase angiogenesis inhibitor, with radio-
therapy to treat tumors occurring at various sites throughout the
body. The finding that some patients remain free of distant
progression raises the possibility that even a brief course of
sunitinib during radiotherapy may offer some protective effect on
micrometastases. Extensive preclinical data and rapidly accumu-
lating human data suggests that sunitinib decreases immunosup-
pressive MDSC and Treg cells [13,30]. While total body radiation
is immunosuppressive, accumulating preclinical data suggests that
local radiation may enhance antitumor immunity by priming the
tumor microenvironment [31]. Most recently reported by Lee
et al., mice that received ablative radiotherapy were found to have
dramatically increased T cells in draining lymphoid tissues, leading
to reduction in primary tumor burden or distant metastases in a
CD8+ T cell-dependent fashion [32]. Thus, concurrent sunitinib
and local radiotherapy may serve as a platform to improve existing
immunotherapeutic approaches. Further analysis of patients
treated with concurrent sunitinib and radiotherapy is underway
in our laboratory. Additionally, bone marrow derived cells,
including MDSC, have been implicated in tumor vasculogenesis
and resistance to angiogenesis inhibitors and radiotherapy [33].
In summary, concurrent sunitinib and image-guided radiother-
apy represents a novel approach to the treatment of patients with
oligometastases that warrants further clinical and translational
study.
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